RxDoctor Payments Data

Ian McGuinness, MD

Neurology · Huntsville, ALNPI 1710374616

Payments from drug & device makers

$17,013in general payments, 2019–2025

Across 1,086 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Pfizer$1K
  • Novartis$1K
  • Argenx US, Inc.$829
  • Neurocrine Biosciences, Inc.$681
  • plus $9K from 52 others

What the payments were for

  • Speaking & faculty fees$540%
  • Food & beverage$16,934100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie191$2,206
UCB, Inc.168$1,840
Pfizer118$1,422
Novartis65$1,127
Argenx US, Inc.33$829
Neurocrine Biosciences, Inc.30$681
Acadia Pharmaceuticals Inc35$636
AstraZeneca(2 entities)32$635
Amgen(2 entities)35$610
MDD US Operations, LLC12$590
Genentech USA, Inc.29$537
Lilly USA, LLC32$419
Neurelis, Inc.26$415
Otsuka America Pharmaceutical, Inc.18$413
TG Therapeutics, Inc.20$393
SK Life Science, Inc.24$370
Eisai Inc.20$301
Lundbeck LLC17$279
Acorda Therapeutics, Inc15$271
Catalyst Pharmaceuticals, Inc.16$258
Biogen15$249
Jazz Pharmaceuticals Inc.12$220
Merz Pharmaceuticals, LLC7$151
EMD Serono, Inc.7$145
Grifols USA, LLC7$144
Johnson & Johnson(2 entities)6$144
CSL Behring5$132
Bristol Myers Squibb7$127
Takeda Pharmaceuticals U.S.A., Inc.6$119
Sumitomo Pharma America, Inc.6$116
Octapharma USA, Inc.5$103
Kyowa Kirin, Inc.6$94
Sunovion Pharmaceuticals Inc.7$93
Avanir Pharmaceuticals, Inc.5$93
Impel Pharmaceuticals Inc.6$93
Biohaven Pharmaceutical Holding Company Ltd.5$86
Scilex Pharmaceuticals Inc.5$74
C2n Diagnostics, LLC3$58
Supernus Pharmaceuticals, Inc.3$55
Teva Pharmaceuticals USA, Inc.3$54
Life Molecular Imaging Ltd2$39
Greenwich Biosciences, Inc.1$37
Harmony Biosciences LLC2$37
Boston Scientific1$31
Biohaven Pharmaceuticals, Inc.1$30
Amneal Pharmaceuticals LLC2$27
Ipsen Biopharmaceuticals, Inc1$24
Banner Life Sciences, LLC1$23
Sanofi1$23
Xeris Pharmaceuticals, Inc.1$23
Medtronic1$21
Aucta Pharmaceuticals, Inc.4$20
Cala Health, Inc.1$19
Immedica Pharma US, Inc.1$18
Avion Pharmaceuticals1$16
Cycle Pharmaceuticals Inc1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$14
Tanabe Pharma America, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,013 in reported general payments places this provider in the 65th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$179,904
Medicare patients
626
Services billed
1,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate56$102,629
Aimovig AutoinjectorErenumab-Aooe69$69,397
RexultiBrexpiprazole23$47,698
QuliptaAtogepant28$41,247
XcopriCenobamate30$36,164
UbrelvyUbrogepant30$32,939
Emgality PenGalcanezumab-Gnlm23$29,508
BriviactBrivaracetam17$24,252
Memantine Hcl322$12,616
Lacosamide74$10,540
Levetiracetam190$7,881
Duloxetine Hcl149$7,096
Gabapentin271$5,870
Pregabalin30$4,175
Divalproex Sodium ErDivalproex Sodium51$3,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$1,422$102,62956 claims
AbbVieQulipta, Ubrelvy$2,206$74,18658 claims
Otsuka America Pharmaceutical, Inc.Rexulti$413$47,69823 claims
SK Life Science, Inc.Xcopri$370$36,16430 claims
UCB, Inc.Briviact$1,840$24,25217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 neurology providers in Alabama.

Other neurology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →